Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DD1E6R
|
|||
| Drug Name |
VLX-1005
|
|||
| Synonyms |
ML355; 1532593-30-8; ML355 free base; ML-355; VLX-1005; N-(1,3-benzothiazol-2-yl)-4-[(2-hydroxy-3-methoxyphenyl)methylamino]benzenesulfonamide; JKU4XCC48Y; CHEMBL3113165; ML 355; N-(1,3-benzothiazol-2-yl)-4-{[(2-hydroxy-3-methoxyphenyl)methyl]amino}benzene-1-sulfonamide; N-(benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide; Benzenesulfonamide, N-2-benzothiazolyl-4-(((2-hydroxy-3-methoxyphenyl)methyl)amino)-; N-2-Benzothiazolyl-4-(((2-hydroxy-3-methoxyphenyl)methyl)amino)benzenesulfonamide; N-2-benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]-benzenesulfonamide; NCGC00263773-03; N-2-Benzothiazolyl-4-[[(2-hydroxy-3-methoxyphenyl)methyl]amino]benzenesulfonamide; ZR5; UNII-JKU4XCC48Y; GTPL8752; SCHEMBL16646023; VLX1005; CHEBI:195557; BCP28954; EX-A1987; VLX 1005; BDBM50447175; s6557; AKOS030526578; CS-3351; NCGC00263773-01; NCGC00263773-18; AC-36858; BS-15552; HY-12341; A908037; Q27087172; N-(1,3-benzothiazol-2-yl)-4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonamide; N-(Benzo[d]thiazol-2-yl)-4-(2-hydroxy-3-methoxybenzylamino)benzenesulfonamide; ML-355; ML-355;N-(Benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Heparin-induced thrombocytopenia [ICD-11: 3B64.12; ICD-10: D69, D69.5] | Phase 2 | [1] | |
| Company |
Veralox Therapeutics Frederick, MD
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H19N3O4S2
|
|||
| Canonical SMILES |
COC1=CC=CC(=C1O)CNC2=CC=C(C=C2)S(=O)(=O)NC3=NC4=CC=CC=C4S3
|
|||
| InChI |
InChI=1S/C21H19N3O4S2/c1-28-18-7-4-5-14(20(18)25)13-22-15-9-11-16(12-10-15)30(26,27)24-21-23-17-6-2-3-8-19(17)29-21/h2-12,22,25H,13H2,1H3,(H,23,24)
|
|||
| InChIKey |
OWHBVKBNNRYMIN-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Arachidonate 12-lipoxygenase, 12R-type (ALOX12B) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05785819) A Randomized, Double-Blind, Phase 2 Pilot Study of VLX-1005 Versus Placebo in Participants With Suspected Heparin Induced Thrombocytopenia Treated With Background Standard of Care. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Veralox Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.